The 14 most recent market catalysts affecting $PGNY, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 8, 2026
Corporate Catalyst
Bullish
Impact 55
Citizens Maintains Market Outperform on Progyny, Raises Price Target to $33
Citizens analyst Constantine Davides has maintained a 'Market Outperform' rating on Progyny (PGNY) and raised the price target from $31 to $33. This action signals continued confid…
Aug 20, 2026
Corporate Catalyst
Neutral
Impact 65
Wells Fargo Initiates Coverage On Progyny with Overweight Rating, Announces Price Target of $37
Wells Fargo analyst Stan Berenshteyn has initiated coverage on Progyny (PGNY) with an 'Overweight' rating and a price target of $37. This event is significant because new analyst c…
Aug 13, 2026
Corporate Catalyst
Bullish
Impact 55
Truist Securities Maintains Buy on Progyny, Raises Price Target to $36
Truist Securities analyst Jailendra Singh has maintained a 'Buy' rating on Progyny and raised the price target from $33 to $36. This action signals increased confidence from the an…
Aug 7, 2026
Corporate Catalyst
Bearish
Impact 85
Progyny shares are trading lower after the company reported Q2 financial results and lowered its FY26 sales guidance with its midpoint below estimates. Also, the company issued Q3GAAP EPS and sales guidance below estimates.
This headline is a significant negative catalyst for Progyny (PGNY). The combination of missing Q2 estimates, issuing lower-than-expected Q3 guidance, and, critically, reducing the…
Aug 6, 2026
Corporate Catalyst
Bearish
Impact 95
Progyny shares are trading lower after the company reported Q2 financial results and lowered its FY26 sales guidance with its midpoint below estimates. Also, the company issued Q3GAAP EPS and sales guidance below estimates.
The headline indicates a strong negative corporate catalyst for Progyny (PGNY). The combination of missing Q2 financial results, a significantly lowered long-term sales guidance (F…
Aug 6, 2026
Corporate Catalyst
Neutral
Impact 75
Progyny Sees Q3 GAAP EPS $0.30-$0.33 vs $0.34 Est
Progyny (PGNY) has pre-announced its Q3 GAAP EPS guidance, indicating a range of $0.30-$0.33, which is slightly below the Street's expectation of $0.34. This is a significant corpo…
Aug 6, 2026
Corporate Catalyst
Neutral
Impact 75
Progyny Sees Q3 Adj EPS $0.50-$0.52 vs $0.33 Est; Sees Sales $335.000M-$345.000M vs $350.185M Est
Progyny (PGNY) has provided Q3 guidance that presents a mixed picture for investors. The company expects adjusted EPS to be $0.50-$0.52, notably higher than the analyst estimate of…
Aug 6, 2026
Corporate Catalyst
Bearish
Impact 80
Progyny Raises FY2026 Adj EPS Guidance from $1.98-$2.09 to $2.04-$2.10 vs $1.29 Est; Lowers FY2026 Sales Guidance from $1.365B-$1.405B to $1.360B-$1.385B vs $1.384B Est
Progyny filed an 8-K to update its financial guidance for fiscal year 2026. The company raised its adjusted EPS guidance from $1.98-$2.09 to $2.04-$2.10, significantly above the an…
Aug 6, 2026
Corporate Catalyst
Bullish
Impact 75
Progyny Q2 Adj. EPS $0.55 Beats $0.34 Estimate, Sales $350.511M Beat $348.682M Estimate
Progyny announced its Q2 earnings, reporting an adjusted EPS of $0.55, which substantially exceeded the analyst consensus of $0.34. Sales also beat estimates, coming in at $350.511…
Jul 28, 2026
Corporate Catalyst
Bullish
Impact 55
Barclays Downgrades Progyny to Equal-Weight, Raises Price Target to $34
Barclays analyst Peter Warendorf downgraded Progyny (PGNY) from Overweight to Equal-Weight, signaling a reduced conviction in the stock's outperformance relative to the broader mar…
Jul 24, 2026
Corporate Catalyst
Bullish
Impact 55
BTIG Maintains Buy on Progyny, Raises Price Target to $40
BTIG analyst David Larsen maintained a 'Buy' rating on Progyny (PGNY) and raised the price target from $30 to $40. This action indicates increased confidence from the analyst in Pr…
Jul 21, 2026
Corporate Catalyst
Bullish
Impact 55
Canaccord Genuity Maintains Buy on Progyny, Raises Price Target to $36
Canaccord Genuity analyst Richard Close has maintained a 'Buy' rating on Progyny (PGNY) and raised the price target from $30 to $36. This indicates a continued bullish stance on th…
Jul 15, 2026
Market Technicals
Bullish
Impact 65
Top 3 Health Care Stocks That May Implode This Month
The filing identifies Progyny (PGNY), 10X Genomics (TXG), and Privia Health Group (PRVA) as health care stocks with high RSI values, specifically above 70, which is typically consi…
Jul 13, 2026
Market Technicals
Bullish
Impact 55
Keybanc Maintains Overweight on Progyny, Raises Price Target to $35
Keybanc analyst Scott Schoenhaus maintained an 'Overweight' rating on Progyny (PGNY) and raised the price target from $30 to $35. This action signals continued confidence in the co…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.